Pneumococcal conjugate vaccine + pneumococcal polysaccharide vaccine
Pneumococcal conjugate vaccine + pneumococcal polysaccharide vaccine has been studied in 1 paper since 2024: 1 observational study in people. The newest paper, Feb 1, 2024: “Effects of sequential vs single pneumococcal vaccination on cardiovascular diseases among older adults: a population-based cohort study”.
1 paper studies it1 findingUpdated
“Compared with those receiving a single vaccine, those receiving sequential dual vaccination had a lower risk of CVD [HR (95% CI): 0.75 (0.71, 0.80), P < 0.001].”
- 1 lab in 1 country
- Funders: Amgen and 8 more
- 1 of 1 finding with company ties
- Humans1
What is Pneumococcal conjugate vaccine + pneumococcal polysaccharide vaccine linked with?
1Studies link Pneumococcal conjugate vaccine + pneumococcal polysaccharide vaccine with 1 measure, most often cardiovascular disease (1 study).
Cardiovascular disease
downin humans1HR 0.75
1 study
Cardiovascular disease
downin humans1HR 0.75
Pneumococcal conjugate vaccine + pneumococcal polysaccharide vaccine is linked with a lower risk of cardiovascular disease in humans (compared with single pneumococcal vaccination) (HR 0.75, 95% CI 0.71-0.80).
“Compared with those receiving a single vaccine, those receiving sequential dual vaccination had a lower risk of CVD [HR (95% CI): 0.75 (0.71, 0.80), P < 0.001].”
Humanscompared with single pneumococcal vaccination1.89 years
International journal of epidemiology